Evaluation of response using FDG-PET/CT and diffusion weighted MRI after radiochemotherapy of pancreatic cancer: a non-randomized, monocentric phase II clinical trial—PaCa-DD-041 (Eudra-CT 2009-011968-11)

BACKGROUND: Pancreatic cancer is a devastating disease with a 5-year survival rate of 20–25%. As approximately only 20% of patients diagnosed with pancreatic cancer are initially staged as resectable, it is necessary to evaluate new therapeutic approaches. Hence, neoadjuvant (radio)chemotherapy is a...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Strahlenther Onkol
Autors principals: Zimmermann, Carolin, Distler, Marius, Jentsch, Christina, Blum, Sophia, Folprecht, Gunnar, Zöphel, Klaus, Polster, Heike, Troost, Esther G. C., Abolmaali, Nasreddin, Weitz, Jürgen, Baumann, Michael, Saeger, Hans-Detlev, Grützmann, Robert
Format: Artigo
Idioma:Inglês
Publicat: Springer Berlin Heidelberg 2020
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7801319/
https://ncbi.nlm.nih.gov/pubmed/32638040
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00066-020-01654-4
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars